Kura Oncology (NASDAQ:KURA) Lowered to Sell Rating by StockNews.com

StockNews.com cut shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research report report published on Wednesday morning.

Other analysts have also issued research reports about the company. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and cut their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Stock Up 7.4 %

KURA stock opened at $10.80 on Wednesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17. The stock has a market cap of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86. The company’s 50 day moving average is $17.88 and its 200 day moving average is $19.69.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of KURA. nVerses Capital LLC bought a new position in shares of Kura Oncology during the third quarter valued at approximately $25,000. SG Americas Securities LLC bought a new position in Kura Oncology in the 1st quarter worth $110,000. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology in the 3rd quarter worth about $146,000. Quarry LP purchased a new stake in shares of Kura Oncology in the 2nd quarter worth about $196,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Kura Oncology during the 3rd quarter valued at about $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.